NxStage

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch NxStage and buy or sell other stocks, ETFs, and their options commission-free!

About NXTM

NxStage Medical, Inc. is a medical technology company, which develops, manufactures, and markets products for the treatment of ESRD and acute kidney failure. It operates through the following business segments: System One, In-Center, and Services. 

CEO
Craig Cordola, MBA, EdD
CEOCraig Cordola, MBA, EdD
Employees
Employees
Headquarters
Waltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded
1998
Founded1998
Employees
Employees

NXTM Key Statistics

Market cap
2.00B
Market cap2.00B
Price-Earnings ratio
-380.23
Price-Earnings ratio-380.23
Dividend yield
Dividend yield
Average volume
2.38M
Average volume2.38M
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$30.00
52 Week high$30.00
52 Week low
$23.17
52 Week low$23.17

Stock Snapshot

As of today, NxStage(NXTM) shares are valued at $29.99. The company's market cap stands at 2B, with a P/E ratio of -380.23.

On 2026-04-15, NxStage(NXTM) shares started trading at —, with intraday highs of — and lows of —.

Trading volume for NxStage(NXTM) stock has reached 0, versus its average volume of 2.38M.

Over the past 52 weeks, NxStage(NXTM) stock has traded between a high of $30.00 and a low of $23.17.

Over the past 52 weeks, NxStage(NXTM) stock has traded between a high of $30.00 and a low of $23.17.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.